Top 5 Drug Type | Count |
---|---|
Small molecule drug | 24 |
Biosimilar | 9 |
Fusion protein | 8 |
Antibody drug conjugate (ADC) | 7 |
Recombinant polypeptide | 5 |
Target |
Mechanism FOLR1 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date14 Nov 2022 |
Target |
Mechanism GLP-1R agonists |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date05 Dec 2017 |
Target |
Mechanism PDE4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date05 Jul 2010 |
Start Date26 Nov 2024 |
Sponsor / Collaborator |
Start Date20 Nov 2024 |
Sponsor / Collaborator |
Start Date30 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Filgrastim biosimilar (Jiuyuan Gene) ( CSF-3R ) | Neutropenia More | Approved |
Liraglutide biosimilar (Zhongmei Huadong) ( GLP-1R ) | Obesity More | Approved |
Antipyrine/Caffeine/Citric Acid ( A1R x A2aR x COX-2 ) | Sedation More | Approved |
Acetohydroxamic Acid | Urinary Calculi More | Approved |
Alogliptin Benzoate ( DPP-4 ) | Diabetes Mellitus, Type 2 More | Approved |